Mode
Text Size
Log in / Sign up
N/A Completed N=206

RPS InflammaDry Detector™ to Determine MMP-9 Levels in Tears

Source: ClinicalTrials.gov NCT01313351 ↗
Enrolled (actual)
206
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Sensitivity and Specificity of InflammaDry Detector Compared to Clinical Assessment at Confirming a Diagnosis of Dry Eyes. — 85; 94 percentage of cases

Summary

The RPS InflammaDry Detector™ is intended to detect elevated MMP-9 in human tears to aid in the diagnosis of patients with signs or symptoms of dry eye disease, in conjunction with other methods of clinical evaluation.

Outcome Measures

OutcomeResultp-value
PRIMARY
Sensitivity and Specificity of InflammaDry Detector Compared to Clinical Assessment at Confirming a Diagnosis of Dry Eyes.
85; 94

Eligibility Criteria

INCLUSION CRITERIA

Patients older than 18 years of age, who meet the following criteria related to the clinical history and signs will be enrolled:

Group 1: Clinical Dry Eyes

Clinical History Criteria

An Ocular Surface Disease Index (OSDI) of greater than or equal to 13 - [Appendix #2]

Clinical Signs Criteria - All of the following must be present

  • Schirmer's Tear Test (with anesthesia) < 10 mm over 5 minutes
  • Tear Film Break Up Time (TBUT) < 10 seconds
  • Total Corneal Staining ≥ 1 [Appendix #1]
  • At least 1/2 of all patients enrolled will have a Schirmer's Tear Test < 5 mm or demonstrate corneal staining ≥ 2 [Appendix #1]

Group 2: Clinical Normal Non-Dry Eyes

Clinical History Criteria

An Ocular Surface Disease Index (OSDI) of < 7 - [Appendix #2]

Clinical Signs Criteria - All 3 of the following must be present

  • Schirmer's Tear Test (with anesthesia) ≥ 10 mm over 5 minutes
  • Tear Film Break Up Time (TBUT) ≥ 10 seconds
  • Total Corneal Staining = 0 [Appendix #1]

EXCLUSION CRITERIA

  • Patients with allergy to corn starch, talcum powder, or dacron
  • Patients with prior eye injury, trauma, or ocular surgery within the previous 3 months
  • Patients with non-dry eye ocular inflammation, uveitis, history of herpetic keratitis or zoster keratitis
  • Patients with history of a recent ocular infection within the prior 1 month
  • Use of oral doxycycline or topical macrolides (AzaSite) within 1 month
  • Patients currently receiving, or received in the last 2 weeks of the study , certain medications including topical or systemic corticosteroids, topical or systemic Nonsteroidal (NSAIDs) therapy, topical cyclosporine, or other immunosuppressive therapy
  • Patients who are pregnant or lactating
  • Before initialization of the study, patients must not have used any topical medications, including artificial tears during the previous 2 hours
  • The use of Rigid-Gas permeable contact lenses or the use of soft-contact lenses within 1 month of the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01313351). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search